FDA Sparks US Rebound in Early Feasibility Device Trials

article image

Early feasibility studies are returning to the US thanks to FDA’s recent initiative. Early data indicates that the regulatory process is working smoothly, but industry and hospitals are lagging behind.

One of the chief areas of frustration for the medtech industry with the FDA in the early 2000s was the extended review times required for regulators to approve innovative devices compared with those in other countries, particularly the CE mark process in Europe. As a result, US patients were not getting access to new technologies until several years after these products were available to the rest of the world.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: